The efficacy of adjuvant chemotherapy after total mesorectal excision without selective lateral lymph node dissection for locally advanced rectal cancer
Shin Kameishi, Toshifumi Yamaguchi, Hiroki Hamamoto, Dai Okemoto, Nanako Matsuo, Takako Ikegami, Hiroyuki Kodama, Hiroki Yukami, Elham Fakhrejahani, Sang-Woong Lee, Hiroki Nishikawa · 2025
Read The efficacy of adjuvant chemotherapy after total mesorectal excision without selective lateral lymph node dissection for locally advanced rectal cancer by Shin Kameishi, Toshifumi Yamaguchi, Hiroki Hamamoto, Dai Okemoto, Nanako Matsuo, Takako Ikegami, Hiroyuki Kodama, Hiroki Yukami, Elham Fakhrejahani, Sang-Woong Lee, Hiroki Nishikawa (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12714797.txt.
Description
Shin Kameishi and co-authors review in 2025 whether drug treatment after a standard rectal cancer operation helps patients stay free of relapse. The operation removes the rectum's fatty envelope, and some teams also remove side lymph nodes. Their hospital skipped the node removal, and the benefit of follow-up drugs in that setting was unclear.
Records covered 117 patients treated over a decade. Three years after surgery, about seventy-four percent were free of relapse and about ninety-six percent were alive. No factor the team tested, from tumor site to drug mix, clearly forecast relapse on its own. The authors judge the drug course a sound partner to the operation.
Catalog record
| CREATOR | Shin Kameishi, Toshifumi Yamaguchi, Hiroki Hamamoto, Dai Okemoto, Nanako Matsuo, Takako Ikegami, Hiroyuki Kodama, Hiroki Yukami, Elham Fakhrejahani, Sang-Woong Lee, Hiroki Nishikawa |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |